Lipidor AB (publ) updates timetable for results from ongoing phase III study – marginal shift in results reporting

Lipidor AB (Nasdaq First North: LIPI) today announces that results from the ongoing phase-III study, of calcipotriol spray against mild to moderate psoriasis, will be presented in January 2020. This represents a marginal delay from the previously communicated timetable.

“As a result of a minor delay at the CRO (clinical research organization) that conducted the study, we can now conclude that delivery of data from the study to the Swedish statistics consultant who will analyze data and confirm results will coincide with the Christmas and New Year holidays. This means that Lipidor will first receive the results to be presented in January. This marginal delay has no commercial significance for Lipidor,” says Ola Holmlund, CEO, Lipidor AB.

“We have previously communicated that we expected to be able to present the results of the study in December, and since there are many of us who are looking forward to the report of the study results, we would like to announce this change to the timetable.”

For more information, please contact

Ola Holmlund, CEO
Phone: +46 72 50 70 369
E-mail: ola.holmlund@lipidor.se

Certified Adviser

Corpura Fondkommission AB
Telephone: +46 76 85 32 822
E-mail: ca@corpura.se

About Lipidor AB

Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.